Raymond James Financial »

Halozyme Therapeutics shares owned by Raymond James Financial

Quarter-by-quarter ownership of Halozyme Therapeutics shares owned by Raymond James Financial from 13F filings

Historical chart of Raymond James Financial investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Raymond James Financial consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Raymond James Financial

Quarter filed Position value Share count Share price at filing
2026-06-30 $14k 13k 1.11
2026-03-31 $19k 18k 1.04
2025-12-31 $37k 34k 1.08

More positions owned by Raymond James Financial

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Ishares Tr Core Us Aggbd Et (AGG)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Microsoft Corporation (MSFT)
Broadcom (AVGO)
Amazon (AMZN)
JPMorgan Chase & Co. (JPM)
Alphabet Cap Stk Cl A (GOOGL)
Ishares Tr Core Msci Eafe (IEFA)
State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Ishares Tr Core S&p500 Etf (IVV)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Ishares Tr Core S&p Mcp Etf (IJH)
Wal-Mart Stores (WMT)

View all positions for Raymond James Financial

Top funds holding Halozyme Therapeutics

M&G
Steelhead Partners
Jpmorgan Chase & Co
Citadel Advisors
Silverback Asset Management
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Citigroup
Tpg Gp A
Point72 Asset Management
Balyasny Asset Management
Advent Capital Management
MacKay Shields
Calamos Advisors
Huntington Asset Advisors
Pier 88 Investment Partners

View all funds holding Halozyme Therapeutics